EHP-101, a cannabidiol-based experimental therapy for multiple sclerosis, was able to recover myelin in damaged nerve fibers and lessen neuroinflammation in a mouse model of MS, data show.
Emerald Health Therapeutics, the manufacturer of EHP-101 also announced plans to open Phase 2 clinical trials in patients by the close of this year.
The data on EHP-101 were shared at the 29th Annual Symposium of the International Cannabinoid Research Society (ICRS), Held June 30 – July 3 in Maryland, and suggest that EHP_101 may be a potential remyelination therapy. Click on the link to find the rest of this article at http://multiplesclerosisnewstoday.com released on July 9th, 2019, By Ana Pena